Iota-carrageenan (carragelose) as a new possibility of symptomatic proceedings respiratory viral infections Review article

Main Article Content

Jarosław Woroń

Abstract

During the autumn–winter time, both children and adults, increasing the incidence of upper respiratory tract. Improper treated, usually symptomatic viral infections can be a source of complications that often require hospitalization. Treatment of viral infections of the upper respiratory tract is symptomatic. One of the possible responses in these indications is the use of products containing carragelose that by acting on the barrier mechanism impede the invasion of the virus to cells of the respiratory tract.

Article Details

How to Cite
Woroń , J. (2016). Iota-carrageenan (carragelose) as a new possibility of symptomatic proceedings respiratory viral infections. Medycyna Faktow (J EBM), 9(4(33), 372-375. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2215
Section
Articles

References

1. DiPiro J.T., Talbert L.R., Yee G.C. et al.: Pharmacotherapy, a pathophysiologic approach. McGraw-Hill Education, New York 2016.
2. Bauer L.A.: Applied Clinical Pharmacokinetics. McGraw-Hill Education, New York 2014.
3. Chiu Y.H., Chan Y.L., Tsai L.W. et al.: Prevention human enterovirus 71 infection by kappa carrageenan. Antiviral Research 2012; 95: 128-134.
4. Eccles R.: Understanding the symptoms of the common cold and influenza. Lancet Infect. Dis. 2005; 5: 718-725.
5. Grassauer A., Weinmuellner R., Meier C. et al.: Iota-Carrageenan is a potent inhibitor of rhinovirus infection. Virol. J. 2008; 5: 107-120.